The Association between Treatment for Metabolic Disorders and Breast Cancer Characteristics

Table 2

Histological characteristics.

Population	Histology				Grade		ER		PR		Ki67 (%)		P53 (%)		Angiolymphatic invasion		PNI
	IDC (%)	ILC (%)	Other^2 (%)		Mean (SD)		Mean (SD)		Mean (SD)		Mean (SD)		Mean (SD)		Yes (%)		Yes (%)
All (671)	80.9	12.2	6.9	—	2.02 (0.59)	—	2.47 (0.57)	—	1.47 (1.19)	—	15.91 (13.58)	—	6.45 (16.96)	—	6.1	—	4.5	—
Metformin^3 (60)	76.7	15	8.3	0.683	2 (0.63)	0.846	2.59 (0.4)	0.032	1.29 (1.05)	0.217	13.7 (11.1)	0.204	6.96 (14.7)	0.828	3.4	0.368	5.1	0.742
Insulin^3 (9)	77.8	11.1	11.1	0.878	1.86 (0.38)	0.474	2.49 (0.67)	0.948	1.12 (0.94)	0.371	9.5 (4.64)	0.017	8.5 (20.3)	0.765	22.2	0.041	0	0.512
Statins^3 (208)	79.8	11.1	9.1	0.266	2.07 (0.5)	0.193	2.48 (0.55)	0.916	1.41 (1.02)	0.346	16.78 (14.53)	0.318	6.45 (15.61)	0.999	7.8	0.212	4.9	0.768
Levothyroxine^3 (62)	69.4	16.1	14.5	0.02	2.02 (0.55)	0.94	2.47 (0.52)	0.999	1.37 (1.27)	0.488	15.28 (12.64)	0.727	5.92 (16.56)	0.84	3.3	0.339	1.6	0.257

value refers to the comparison of each variable between patients who used the specified medication to the rest of the cohort.
²Another subtype histology includes medullary, mucinous, papillary, and tubular carcinomas.
Medication usage was not available for 15 patients.
ER: estrogen receptor, PNI: perineural invasion, and PR: progesterone receptor.
³Median duration of medications usage (months, range): metformin 50.5 (1–80.5), insulin 56 (10–126), statins 72 (1–168), and levothyroxine 113 (8–168).